In conclusion, FX improves glucose tolerance and insulin sensitivity, decreases lipogenesis and increases lipid oxidation in the liver of HFD rats, implying a potential application in the treatment of non-alcoholic fatty liver disease. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.